(Reuters) -Jazz Pharmaceuticals will acquire biotech firm Chimerix for about $935 million to gain access to its experimental drug to treat a rare brain tumor, the companies said on Wednesday.
(Reporting by Mariam Sunny in Bengaluru; Editing by Leroy Leo)
Comments